The Food and Drug Administration today authorized Innovative Health Solutions Inc. to market an electrical nerve stimulator device to relieve opioid withdrawal symptoms when placed behind the patient’s ear. Previously approved for use in acupuncture, the NSS-2 Bridge device reduced symptoms for patients undergoing opioid withdrawal during a clinical study by at least 31% within 30 minutes, based on the clinical opiate withdrawal scale. Sixty-four of the 73 patients in the study transitioned to medication assisted therapy after five days using the device. “The FDA is committed to supporting the development of novel treatments, both drugs and devices, that can be used to address opioid dependence or addiction, as well as new, non-addictive treatments for pain that can serve as alternatives to opioids,” said FDA Commissioner Scott Gottlieb, M.D.

Related News Articles

Headline
The National Academies of Sciences Engineering, and Medicine yesterday released recommendations for improving outcomes and metrics associated with four grant…
Headline
As the nation celebrates National Nurses Week in the midst of the COVID-19 pandemic, nurses' commitment and strength is inspiring communities across the…
Headline
The American Organization for Nursing Leadership yesterday unveiled a new resource to provide nurse leaders with practical tips and effective strategies for…
Headline
The Centers for Medicare & Medicaid Services recently announced a six-month delay in implementation of its Innovation Center Maternal Opioid Misuse (MOM)…
Headline
This year was already designated as the International Year of the Nurse and the Midwife before our current pandemic re-emphasized nurses’ vital role in caring…
Blog
When the World Health Assembly designated 2020 as the International Year of the Nurse and the Midwife, they had no idea a pandemic would envelop the world the…